Return to CDC/FDA Alert Section
Data on cancer described by A.L. Mayburd et al
April 28th, 2008
2008 APR 28 -- According to recent research from the United States, "New efforts to guide and prioritize the selection of cancer drug targets are urgently needed, as is evident by the slow development of novel anti-cancer agents and the narrow therapeutic index of existing drugs. Given these limitations, the current study was conducted to explore the classification features defining the therapeutic success that can result from targeting a particular gene." "Classification was based on extracting features specific to known successful anti-cancer targets and combining them in a linear classifier, resulting in calculation of an enrichment score for each gene. Extended description, the search tool used in this study, enriched existing drug target candidates by up to 10-fold at an similar to 50 recall rate, covering similar to 24 000 genes or similar to 80 of genome. More importantly, the target category with high attrition rate was classified from target category with low attrition rate, allowing to refine the drug development portfolios. Biological relevance of the parameters comprising the enrichment score was explored. Enrichment in cancer-specific effects was independently demonstrated by literature analysis," wrote A.L. Mayburd and colleagues. The researchers concluded: "Imposing these enrichment scores on existing structural, pathway and phenotype-based procedures for prospective target selection may enhance the efficiency and accuracy of target identification and accelerate drug design." Mayburd and colleagues published their study in Bioinformatics (Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets. Bioinformatics, 2008;24(3):389-395). For additional information, contact A.L. Mayburd, CPA Global LLC, 1725 Duke St., Alexnadria, VA 22314, USA. Publisher contact information for the journal Bioinformatics is: Oxford University Press, Great Clarendon St., Oxford OX2 6DP, England. Keywords: United States, BioInformatics LLC, Biotechnology Business, Biotechnology Company, Cancer, Drug Development, FDA, Oncology, Pharmaceuticals, Therapy, Treatment, U.S. Food and Drug Administration. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2008, Biotech Business Week via NewsRx.com.
Return to CDC/FDA Alert Section
|
